EUR-Lex Access to European Union law
This document is an excerpt from the EUR-Lex website
Supplementary protection certificate for medicinal products
The European Union intends to provide sufficient protection for the development of medicinal products in the interest of public health and also to encourage pharmaceutical research. In view of the above, this Regulation creates a supplementary protection certificate for medicinal products at Community level which makes it possible to rectify disparities in the national systems.
ACT
Council Regulation (EEC) No 1768/92 of 18 June 1992 concerning the creation of a supplementary protection certificate for medicinal products [See amending acts].
SUMMARY
The purpose of the supplementary protection certificate for medicinal products * is to remedy the disparities and shortcomings in national patenting systems for pharmaceutical research. It aims in particular to guarantee sufficient protection for the development of medicinal products in the European Union (EU).
Indeed, the period between the filing of a patent application for a new medicinal product and authorisation to place it on the market constitutes one of the factors which actually reduces the effective protection afforded by the patent and can compromise the amortisation of investment in research. The lack of sufficient protection can also lead research centres based in the Member States to relocate to countries offering better protection.
In order to also guarantee the free movement of medicinal products, the supplementary certificate for the protection of medicinal products also aims to prevent the development of too many disparities in national legislation.
The certificate is issued if the product for which it was requested, as a medicinal product and at the time when the application was filed in a Member State, meets the following conditions:
Furthermore, the certificate applies to the product in the same way as the patent from which it benefits. The Regulation also specifies the arrangements relating to application for and granting of the certificate and likewise the conditions for lapse, invalidity and publicity of the certificate.
The certificate cannot be granted for a period exceeding five years. Furthermore, the duration of protection afforded by a patent and by the certificate cannot exceed 15 years overall for the holder's first marketing authorisation.
From 6 July 2009, this Regulation was repealed by Regulation (EC) No 469/2009.
Key terms in the Act
References
Act |
Entry into force |
Deadline for transposition in the Member States |
Official Journal |
Regulation (EEC) No 1768/92 |
2.1.1993 |
- |
OJ L 182 of 2.7.1992 |
Amending Act(s) |
Entry into force |
Deadline for transposition in the Member States |
Official Journal |
Act of Accession of Austria, Finland and Sweden |
1.1.1995 |
- |
OJ C 241, 29.8.1994 |
Act of Accession of the Czech Republic, Estonia, Cyprus, Latvia, Lithuania, Hungary, Malta, Poland, Slovenia and Slovakia. |
1.5.2004 |
- |
OJ L 236 of 23.9.2003 |
Act of Accession of Bulgaria and Romania. |
1.1.2007 |
- |
OJ L 157 of 21.6.2005 |
Regulation (EC) No 1901/2006 |
26.1.2007 |
- |
OJ L 378 of 27.12.2006 |
Last updated: 24.09.2009